1. New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

    New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

    CAMBRIDGE, Mass., June 2, 2018 /PRNewswire-USNewswire/ -- Why is it so hard to develop drugs for children with cancer? And what can be done about it? Those questions are central to a new study published today in JAMA Oncology that explores new business models for funding drug...

    Read Full Article
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes

    1. As a new era of drug development dawns, scientists are finding cures and treatments for different types of cancers every day. But for a variety of reasons, childhood cancers are being left behind.
    2. When lives are at stake, such lofty prices may seem like price gouging even though such prices may be justified from a cost-effectiveness perspective.
  3. Topics Mentioned

  4. Authors